Acorda Therapeutics Prices Public Offering Of 3.75 Mln Common ...
RTT News - Williamsville,NY,USA
Acorda Therapeutics said it intends to use this offering net proceeds to complete second Fampridine-SR Phase 3 clinical trial and to conduct other ...
See all stories on this topic

Friday's Health Winners & Losers
TheStreet.com - USA
It will use the proceeds for a second phase III clinical trial for Fampridine-SR as well as a new-drug application filing for the product, ...
See all stories on this topic

Accorda enrolls first patient in phase III MS study
Pharmaceutical Business Review - USA
Acorda Therapeutics has begun a second phase III clinical study of Fampridine-SR in multiple sclerosis, with the randomization of its first patient into the ...
See all stories on this topic